Sponsor or institution

Clinical trials and research at Sichuan Baili Pharmaceutical Co., Ltd.

• 76Clinical trials
• 1Country

Newest trials

All recruiting trials (76)

• BL-M08D treatment in melanoma and other solid tumors

  A phase Ib/II study tests BL-M08D1 injections in adults with locally advanced or metastatic melanoma and other solid tumors to see if it is safe and helpful.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07841925

• BL-M08D in patients with digestive tract and other solid tumors

  A early-stage study to see if BL-M08D1 can be safely given and help people with advanced digestive tract cancers and other solid tumors.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07780318

• BL-ARC002 in patients with advanced solid tumors

  This study tests BL-ARC002 to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07763652

• SI-B036 in head and neck and other solid tumors: a first-in-human study

  This early-phase study tests SI-B036 in adults with locally advanced or metastatic head and neck cancers and other solid tumors to see if it is safe and tolerable, and to get initial clues about its activity.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Changsha, Hunan and 1 other locations · NCT07763639

• SI-B036 in locally advanced or metastatic breast cancer and other solid tumors

  Scientists are testing SI-B036 to see if it is safe and tolerable in adults with advanced breast cancer or other solid tumors and to get early signals of whether it might help.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07753226

• BL-B01D1 plus PD-1 therapy vs nab-paclitaxel plus PD-1 therapy in untreated PD-L1-positive locally advanced or metastatic TNBC

  This phase 3 trial tests whether BL-B01D1 with a PD-1 antibody works better than nab-paclitaxel with a PD-1 antibody in women with newly treated, PD-L1-positive, locally advanced or metastatic triple-negative breast cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07729956

• SI-B036 in advanced gastrointestinal and other solid tumors

  This phase 1 trial tests SI-B036 to see if it is safe and tolerable in adults with locally advanced or metastatic gastrointestinal and other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Harbin, Heilongjiang · NCT07678970

• BL-M07D1 vs DS-8201 in HR-positive, HER2-low metastatic breast cancer

  This phase 2 trial tests whether BL-M07D1 can help people with HR-positive, HER2-low breast cancer that has spread or returned, compared with DS-8201.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07678957

• BL-B01D1 plus chemotherapy vs chemotherapy in people with HR+/HER2- breast cancer that can’t be removed or has come back or spread after endocrine therapy

  This phase 3 trial tests whether BL-B01D1 plus physician's choice chemotherapy helps people with HR+/HER2- breast cancer after stopping endocrine therapy compare to chemotherapy chosen by their doctor.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07648914

• BL-B01D1 with Osimertinib before/around surgery for EGFR-mutant resectable NSCLC

  A Phase II/III trial tests if adding BL-B01D1 to osimertinib around surgery helps people with resectable EGFR-mutant non-small cell lung cancer.

  Recruiting at 2 sites Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality and 1 other locations · NCT07642024

• BL-B01D1 plus osimertinib vs osimertinib alone in unresectable EGFR-mutated NSCLC (Stage III) after chemoradiation

  This trial tests whether adding BL-B01D1 to osimertinib helps people with unresectable Stage III EGFR-mutated non-small cell lung cancer who did not progress after platinum-based chemoradiation.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Jinan, Shandong · NCT07640789

• SI-B036 in adults with locally advanced or metastatic solid tumors

  This phase 1 study tests SI-B036 in adults with solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of activity.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07606612

• BL-M07D1 vs physician’s choice chemotherapy after platinum failure in HER2-positive biliary tract cancer

  This Phase 3 trial tests BL-M07D1 against the doctor’s choice chemotherapy in adults with HER2-expressing biliary tract cancer that has progressed after platinum therapy.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Hefei, Anhui and 1 other locations · NCT07606599

• BL-ARC002 in patients with solid tumors

  This early-phase study tests BL-ARC002 in adults with locally advanced or metastatic solid tumors to see if it is safe and how it behaves in the body, and to look for any signs of benefit.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07591155

• BL-B01D1 vs physician’s choice in biliary tract cancer after platinum failure

  This phase 3 trial tests whether BL-B01D1 helps patients with locally advanced or metastatic biliary tract cancer who have already had platinum-based chemotherapy fail, compared with the doctor’s choice treatment.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07582315

• BL-B01D1 with Tislelizumab ± 5-FU as first-line treatment for unresectable, locally advanced recurrent, or metastatic esophageal squamous cell carcinoma

  A phase II/III trial tests BL-B01D1 with tislelizumab, with or without 5-FU, against standard platinum-based chemotherapy plus tislelizumab for adults with unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07554456

• BL-M07D1 plus pertuzumab vs standard therapy in first-line HER2-positive breast cancer

  A Phase 3 trial tests whether adding BL-M07D1 to pertuzumab is as good as or better than docetaxel plus trastuzumab and pertuzumab in patients with newly diagnosed, unresectable or metastatic HER2-positive breast cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT07518173

• BL-B01D1 plus tislelizumab vs platinum-based chemo plus tislelizumab as first-line treatment for extensive-stage small cell lung cancer

  This trial tests whether adding BL-B01D1 to tislelizumab works better than platinum-containing chemotherapy with tislelizumab for adults with extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Zhengzhou, Henan and 1 other locations · NCT07502300

• BL-M24D1 treatment for advanced gastrointestinal and other solid tumors

  This trial will test BL-M24D1 in adults with locally advanced or metastatic gastrointestinal and other solid tumors to see if it is safe, tolerated, and shows early signs of anti-tumor activity.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07279428

• Lutetium [177Lu]-BL-ARC001 for advanced lung, breast, head and neck and other solid tumors

  This study will test a radiolabeled drug called Lutetium [177Lu]-BL-ARC001 in adults with advanced or metastatic solid tumors (such as lung, breast, or head and neck cancers) whose standard treatments have not worked.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07274852

• BL-M07D1 plus pembrolizumab for advanced HER2‑overexpressing non-squamous NSCLC

  This treatment combines BL-M07D1 with pembrolizumab to see if it helps people with unresectable locally advanced or metastatic HER2‑overexpressing non‑squamous non‑small cell lung cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Wuhan, Hubei · NCT07264816

• BL-M24D1 in relapsed or refractory multiple myeloma and other blood cancers

  This early-phase trial tests BL-M24D1 in adults with relapsed or refractory multiple myeloma or other hematologic cancers to see if it is safe and tolerable and to get a first look at its activity.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07255898

• BL-M11D1 in combination with chemotherapy or venetoclax-based therapy for newly diagnosed AML

  A phase 2/3 trial tests BL-M11D1 with standard AML regimens in adults with newly diagnosed acute myeloid leukemia to see if it can be given safely and early signals of benefit.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Tianjin, Tianjin Municipality · NCT07255872

• BL-M24D1 for advanced head and neck and other solid tumors

  This study will try BL-M24D1 in adults with locally advanced or metastatic head and neck squamous cell carcinoma or other solid tumors to see if it is safe and shows early signs of benefit.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07232524

• BL-M24D1 for adults with advanced or metastatic non-small cell lung cancer and other solid tumors

  This trial will test whether BL-M24D1 is safe, how the body handles it, and whether it shows signs of benefit in adults with locally advanced or metastatic non-small cell lung cancer or other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07232420

• Lutetium‑177 BL‑ARC001 for advanced or metastatic gastrointestinal and other solid tumors

  This trial will test whether Lutetium‑177 BL‑ARC001 is safe and shows early benefit in adults with locally advanced or metastatic gastrointestinal or other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Chengdu, Sichuan · NCT07232407

• BL-M07D1 versus pembrolizumab-plus-platinum chemo for first-line HER2‑mutant advanced non-squamous lung cancer

  This trial will test whether BL-M07D1 works better than pembrolizumab combined with platinum chemotherapy as the first treatment for people with HER2‑mutant advanced or metastatic non-squamous non-small cell lung cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT07178795

• BL-M07D1 versus chemotherapy for HER2-positive advanced gastric or gastroesophageal junction cancer

  This trial tests whether BL-M07D1 works better than a doctor's choice of chemotherapy for adults with HER2‑positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma after first‑line anti‑HER2 therapy has failed.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT07152405

• BL-M09D1 for people with advanced non-small cell lung cancer and other solid tumors

  This trial will test whether BL-M09D1 is safe and can shrink tumors in adults with advanced non-small cell lung cancer or other solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07056556

• BL-B01D1 plus pembrolizumab, with or without bevacizumab, for recurrent or metastatic cervical and endometrial cancer

  This trial will try a combination of BL-B01D1 and pembrolizumab, with or without bevacizumab, in adults with recurrent or metastatic cervical or endometrial cancer to see if it shrinks tumors or controls the disease.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT07054567

• BL-B01D1 versus doctor‑chosen chemotherapy for platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer

  This tests whether BL-B01D1 works better than the doctor’s choice of chemotherapy for adults with platinum‑resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06994195

• BL-B01D1 plus lenvatinib for advanced hepatocellular carcinoma

  This trial tests whether adding BL-B01D1 to lenvatinib helps people with advanced hepatocellular carcinoma shrink tumors or slow disease progression.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06986785

• BL-B01D1 plus a PD-1/PD-L1 antibody for advanced biliary tract cancer

  The treatment combines BL-B01D1 with a PD-1/PD-L1 antibody to see if it helps people with advanced biliary tract cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06978114

• BL-B01D1 plus a TKI, with or without pembrolizumab, for advanced kidney cancer

  This trial will test whether adding the experimental drug BL-B01D1 to a standard TKI—with or without the immunotherapy pembrolizumab—helps people with locally advanced or metastatic kidney cancer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06962787

• Comparing BL-M07D1 to standard chemotherapy for HER2-low breast cancer

  This study is testing if a new treatment called BL-M07D1 can work better than standard chemotherapy for people with advanced HER2-low breast cancer.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT06957886

• BL-M09D1 for advanced or metastatic gastrointestinal and other solid tumors

  This trial will test whether a new drug called BL-M09D1 is safe, how the body handles it, and whether it might help adults with locally advanced or metastatic gastrointestinal or other solid tumors that have not responded to standard treatments.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06954077

• Neoadjuvant BL-M07D1 (with or without pertuzumab) versus taxane + trastuzumab + pertuzumab for HER2-positive breast cancer

  This trial will try whether giving the experimental antibody BL-M07D1, with or without pertuzumab, before surgery improves outcomes for people with HER2-positive breast cancer compared with the standard taxane plus trastuzumab and pertuzumab regimen.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Bengbu, Anhui and 29 other locations · NCT06891833

• Injection of GNC-038 antibody for rheumatoid arthritis treatment

  This study is testing a new antibody treatment for people with moderate to severe rheumatoid arthritis to see if it helps them feel better while they continue their usual care.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06857227

• GNC-038 tetra-specific antibody injection for adults with moderate-to-severe systemic lupus erythematosus

  This study will test whether GNC-038, a tetra-specific antibody injection, is safe and can reduce disease activity in adults with moderate-to-severe systemic lupus erythematosus.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06857214

• Combining BL-B01D1 with Osimertinib for treating advanced lung cancer

  This study is testing whether adding a new drug called BL-B01D1 to osimertinib can help people with advanced lung cancer live better compared to just using osimertinib alone.

  Recruiting Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06838273

• BL-M07D1 versus T-DM1 after surgery for HER2‑positive breast cancer with residual invasive disease following neoadjuvant therapy

  This trial will test whether BL‑M07D1 works better than T‑DM1 as additional treatment after surgery for people with HER2‑positive breast cancer who still have invasive cancer following pre-surgery therapy.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Nanjing, Jiangsu and 1 other locations · NCT06830889

• Evaluating BL-M08D1 for patients with advanced lymphoid cancers

  This study is testing a new treatment called BL-M08D1 to see if it is safe and effective for people with advanced lymphoid cancers that haven't responded to other treatments.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Harbin, Heilongjiang · NCT06718634

• Evaluating BL-M08D1 for advanced solid tumors

  This study is testing a new treatment called BL-M08D1 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06718621

• Evaluating GNC-077 for advanced lung cancer and solid tumors

  This study is testing a new drug called GNC-077 to see if it is safe and effective for people with advanced lung cancer and other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06612840

• Evaluating GNC-077 for advanced breast cancer and solid tumors

  This study is testing a new drug called GNC-077 to see if it is safe and effective for people with advanced breast cancer and other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06609187

• Evaluating BL-B01D1 for patients with recurrent glioblastoma

  This study is testing a new drug called BL-B01D1 to see if it can help people with recurrent glioblastoma who haven't had success with other treatments.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06598787

• Evaluating BL-M17D1 for advanced breast cancer and solid tumors

  This study is testing a new treatment called BL-M17D1 to see if it is safe and effective for people with advanced breast cancer and other solid tumors.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Harbin, Heilongjiang and 1 other locations · NCT06503783

• Evaluating BL-M17D1 for HER2 Positive Gastrointestinal Cancer

  This study is testing a new drug called BL-M17D1 to see if it is safe and effective for people with advanced HER2 positive gastrointestinal cancer and other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06500052

• Evaluating BL-B16D1 for advanced breast cancer and solid tumors

  This study is testing a new treatment called BL-B16D1 to see if it is safe and effective for people with advanced breast cancer and other solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06493864

• Combining BL-B01D1 and PD-1 Antibody for Advanced Lung and Nasopharyngeal Cancers

  This study is testing a new combination of two cancer treatments to see if it can help people with advanced lung and nasopharyngeal cancers feel better and live longer.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06475300

• Evaluating BL-B16D1 for advanced solid tumors

  This study is testing a new treatment called BL-B16D1 to see if it can help people with advanced solid tumors who haven't had success with other therapies.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong · NCT06475131

• Combining BL-B01D1 and PD-1 Antibody for Advanced Triple-negative Breast Cancer

  This study is testing a new combination treatment for people with advanced triple-negative breast cancer to see if it can help shrink their tumors.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06471205

• Evaluating BL-B16D1 for patients with advanced head and neck cancers and other solid tumors

  This study is testing a new treatment called BL-B16D1 to see if it can help people with advanced head and neck cancers and other solid tumors who haven't had success with other therapies.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06469008

• Combination therapy for recurrent or metastatic head and neck cancer

  This study is testing a new combination treatment for adults with recurrent or metastatic head and neck cancer to see if it helps them better than current options.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06437522

• Combination therapy for extensive-stage small cell lung cancer

  This study is testing a new combination treatment for people with extensive-stage small cell lung cancer to see how well it works and what side effects it might have.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06437509

• Combination therapy for advanced bladder cancer

  This study is testing a new combination treatment for people with advanced bladder cancer to see if it helps them feel better and stay safe.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06405425

• Evaluating BL-M07D1 for treating HER2-positive gynecologic cancers

  This study is testing a new treatment called BL-M07D1 to see if it can help women with advanced HER2-positive gynecologic cancers that haven't responded to other therapies.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06131450

• Testing GNC-035 for patients with relapsed or refractory Non-Hodgkin's Lymphoma

  This study is testing a new treatment called GNC-035 to see if it can help people with relapsed or hard-to-treat Non-Hodgkin's Lymphoma feel better.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06066203

• Testing new treatments for advanced HER2 negative breast cancer

  This study is testing two new treatment options for people with advanced HER2 negative breast cancer who haven't had success with standard treatments to see if they can help improve their health.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06042894

• Testing BL-M07D1 for treating certain solid tumors

  This study is testing a new treatment called BL-M07D1 to see if it can safely help people with certain types of advanced solid tumors, especially those related to the urinary and gastrointestinal systems.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06031584

• Testing new treatments for advanced gastrointestinal cancers

  This study is testing three different treatment options for people with advanced gastrointestinal cancers to see which one works best and is safest.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT06008054

• Investigating new treatments for recurrent or metastatic head and neck cancer

  This study is testing two new drugs to see if they can help people with recurrent or metastatic head and neck cancer feel better when other treatments haven't worked.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT06006169

• Testing new treatments for recurrent or metastatic cervical cancer and other gynecological cancers

  This study is testing three different treatment options for women with recurrent or metastatic cervical and other gynecological cancers to see which one works best and is safest.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT05990803

• Testing new treatments for advanced bladder cancer and other solid tumors

  This study is testing two new treatments for people with advanced bladder cancer and other solid tumors who have not had success with standard therapies or can't handle them.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT05965856

• Testing a new drug combination for advanced lung and nasopharyngeal cancers

  This study is testing a new combination of drugs to see if it can help people with advanced lung cancer and nasopharyngeal cancer feel better and tolerate the treatment well.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Chongqing, Chongqing Municipality and 15 other locations · NCT05956587

• Testing new treatments for extensive stage small cell lung cancer

  This study is testing three different treatment options for people with extensive-stage small cell lung cancer who haven't had success with other therapies to see which one works best.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Changchun, Jilin · NCT05924841

• Testing BL-M11D1 for patients with relapsed or refractory acute myeloid leukemia

  This study is testing a new treatment called BL-M11D1 to see if it is safe and tolerable for patients with relapsed or refractory acute myeloid leukemia.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Hefei, Anhui and 7 other locations · NCT05924750

• Evaluating BL-B01D1 for patients with multiple solid tumors, including gynecological cancers

  This study is testing a new treatment called BL-B01D1 to see if it can safely help patients with multiple solid tumors, especially those with gynecological cancers.

  Recruiting Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT05803018

• Evaluating BL-B01D1 for patients with advanced urinary system tumors

  This study is testing a new treatment called BL-B01D1 to see if it is safe and effective for people with advanced urinary system tumors.

  Recruiting Phase 2 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT05785039

• Testing BL-M07D1 for advanced digestive tract and solid tumors

  This study is testing a new treatment called BL-M07D1 to see if it is safe and effective for people with advanced digestive tract and solid tumors.

  Recruiting Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Shanghai, Shanghai Municipality · NCT05631964

• GNC-038 injection for patients with relapsed or refractory non-Hodgkin's lymphoma

  This study is testing a new injection treatment called GNC-038 to see if it can help people with relapsed or hard-to-treat non-Hodgkin's lymphoma feel better.

  Recruiting at 3 sites Phase 1/2 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT05623982

• Investigating BL-B01D1 for advanced breast cancer and other solid tumors

  This study is testing a new treatment called BL-B01D1 to see if it is safe and effective for people with advanced breast cancer and other solid tumors that can't be surgically removed.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Guangzhou, Guangdong and 1 other locations · NCT05470348

• Investigating BL-M07D1 for HER2 Positive Breast Cancer and Other Solid Tumors

  This study is testing a new treatment called BL-M07D1 to see if it can safely help people with advanced HER2-positive breast cancer and other solid tumors.

  Recruiting at 7 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Fuzhou, Fujian and 6 other locations · NCT05461768

• Investigating BL-B01D1 for advanced gastrointestinal tumors and other solid tumors

  This study is testing a new treatment called BL-B01D1 to see if it's safe and effective for people with advanced gastrointestinal and other solid tumors.

  Recruiting at 6 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 5 other locations · NCT05262491

• Investigating BL-B01D1 for advanced solid tumors

  This study is testing a new treatment called BL-B01D1 to see if it's safe and effective for people with advanced solid tumors.

  Recruiting at 8 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Chongqing, Chongqing Municipality and 7 other locations · NCT05194982

• Testing GNC-039 in patients with advanced solid tumors

  This study is testing a new treatment called GNC-039 to see if it is safe and effective for people with advanced solid tumors, including those with relapsed or hard-to-treat gliomas.

  Recruiting at 6 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality and 5 other locations · NCT04794972

Quick answers

How many clinical trials run by Sichuan Baili Pharmaceutical Co., Ltd. are recruiting right now?

76, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

All of them have sites in China. Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 1: 32, Phase 2: 20, Phase 3: 13, Phase 1/2: 7. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →